Overview

This article explores the rapid growth of peptide therapy and the concerns surrounding unverified providers, compounded products, and limited transparency in the peptide market. It explains how patients can evaluate peptide clinics by checking medical oversight, pharmacy sources, prescribing procedures, informed consent, and potential risks. The article also highlights how provider transparency and independent verification can help patients make safer, more informed decisions when considering peptide therapy.

Half Your Gym Is on Peptides. Here's Why That Should Worry You.

Walk into any commercial gym on a Monday morning. There's a reasonable chance one in five people you see is using, or recently used, some form of peptide therapy. Semaglutide for weight loss. BPC-157 for a nagging shoulder. Ipamorelin for recovery. NAD+ because a podcast promised it would reverse aging.

The peptide market isn't emerging. It's mainstream. According to Grand View Research, the global peptide therapeutics market was valued at $140.9 billion in 2025 and is projected to reach $294.6 billion by 2033. And at the consumer level, it's almost entirely unverified.

Mike Paepke, PA-C, MMSc, is a Yale-educated, fellowship-trained physician assistant whose graduate research focused on peptide therapeutics and long-term medical cost implications. He prescribes these compounds. He believes in them when they're used correctly.

"When used correctly" is doing a lot of work in that sentence.

The Market Outran Its Guardrails

Demand came first: health-conscious, fitness-oriented patients with disposable income and a cultural appetite for optimization. Supply followed. Then telehealth erased geography entirely. The clinic prescribing peptides may be in a state a patient has never visited, sourcing from a pharmacy they have never heard of.

In a single 30-mile radius of one metro area, Paepke counted more than 40 clinics, med spas, and telehealth platforms marketing peptide therapy. Credentials ranged from board-certified physicians with published research to aestheticians who added "peptide therapy" to a menu between microblading and lip filler. Multiply that by every metro in the country.

A patient walking in off the street cannot tell the difference.

There is no public registry, certification, or independent verification that lets a consumer check whether a peptide provider has real medical oversight, uses quality-controlled pharmacy sources, follows a legitimate prescribing process, or even employs a licensed prescriber.

So Paepke built one.

What the Screening Found

PepKey evaluates peptide providers on the criteria that actually predict patient safety: medical director credentials, compounding pharmacy transparency, documented prescription process, and informed consent. The platform's scoring methodology assigns each provider a Transparency Score from 0 to 10 across four categories: documentation, patient signal, independent verification, and engagement.

The results are striking. Across 4,048 assessed providers, the average score sits at just 3.36 out of 10, a rating that falls squarely in the "Needs Improvement" category. Only 2 of those 4,048 providers have reached the top "Teal" standard of verified, claimed, and documented transparency.

Paepke's own screening data reinforces why that matters:

The providers doing this right, and many are have no way to prove it. The market rewards marketing over medicine, and the good actors pay for it.

Five Questions to Ask Before Your First Injection

For anyone considering peptide therapy, Paepke outlines five questions that every legitimate provider should be able to answer without hesitation:

1. Who is your medical director, and what is their license number?
No immediate answer means no appointment.

2. Is this FDA-approved or compounded?
Neither answer automatically disqualifies a provider. Not knowing does.

3. Which pharmacy compounds it, and is it licensed and FDA-registered?
Refusing to name the pharmacy is the single biggest red flag in the entire process.

4. What is the prescribing process?
Legitimate care means a real consultation, full health history, and usually labs—before anything ships.

5. What are the risks and side effects?
If the conversation only includes benefits, the patient is being sold to, not treated.

The Window Is Already Closing

This is not hypothetical anymore. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, ending the exemption that had allowed compounders to mass-produce copies during the shortage period.

The regulatory tightening didn't stop there. In April 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, finding no current clinical need for outsourcing facilities to compound these medications in bulk. The agency has also issued dozens of warning letters to compounding pharmacies and telehealth platforms making false or misleading claims about compounded GLP-1 products.

The safety concerns behind that regulatory pressure are real. One published study found that compounded GLP-1 receptor agonists are associated with a greater risk of adverse events, safety concerns, and product quality issues compared to non-compounded products a finding that prompted several major medical societies to recommend against their use altogether.

Patient-specific 503A compounding remains legal in narrow circumstances. A lot of what is being sold in strip malls and Instagram DMs does not meet those circumstances.

The Good Actors Deserve to Be Found

Here is the part that tends to get lost in the broader alarm: there are peptide providers doing this correctly. They have physician oversight, transparent sourcing, rigorous intake processes, and informed patients. The problem is that the current market gives them no way to prove it and gives patients no way to find them.

That's the gap PepKey is designed to close. Rather than accepting marketing claims as evidence, the platform cross-references public records, NPI registries, and provider disclosures to build a verifiable file on each clinic. Scores are not for sale. Missing information stays labeled unverified. And the scoring methodology is published and publicly reviewable.

Of the 4,048 providers currently assessed, 739 fall into the "High Risk" category, meaning critical information is missing from the public record, or red flags are present. Another 1,704 fall under "Needs Improvement." Only 1,603 reach the "Fair" tier, with partial documentation. Two reach the top Teal standard.

Those two providers exist. The bar is achievable. It's just rarely cleared.

What Patients Need to Know Right Now

The patients who get hurt will not be the ones who vetted their provider. They will be the ones who find out their "Ozempic" was never Ozempic after the supply disappears, after the enforcement tightens, after the compounding pharmacy they relied on can no longer legally fill their prescription.

Peptide therapy, used correctly, has genuine clinical value. The answer isn't to avoid it. The answer is to demand the same level of documentation from a peptide clinic that any patient would expect from a physician's office: named oversight, a transparent prescribing process, a disclosed and registered pharmacy source, and a conversation about risks, not just results.

Before the next appointment, check the provider on PepKey. Ask the five questions above. And if the answers aren't immediate, keep looking.

Conclusion

Peptide therapy may offer legitimate clinical benefits when prescribed and monitored appropriately, but the growing market also creates risks for patients who rely solely on marketing claims. Choosing a provider with qualified medical oversight, transparent pharmacy sourcing, proper consultations, and clear information about risks is essential. Patients should ask questions, verify credentials, and research providers carefully before beginning treatment.